Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Cynomolgus / Rhesus macaque FcRn/FCGRT & B2M, Avi Tag (Avitag™), 200 µg  

Recombinant Biotinylated Cynomolgus / Rhesus macaque FcRn/FCGRT & B2M, Avi Tag (Avitag™), 200 µg

MABSol® Recombinant Biotinylated Cynomolgus FcRn / FCGRT & B2M Heterodimer Protein, expressed from human HEK293 cells, Avi tag (Avitag™), His-Tag, Strep II tag

Synonyms: recombinant, cynomolgus, protein, biotinylated, FcRn, FCGRT & B2M

More details

FCM-C82W5-200

1 380,00 €

Background: FCGRT & B2M heterodimer protein (FcRn complex) consist of two subunits: p51 (equivalent to FCGRT), and p14 (equivalent to beta-2-microglobulin), and forms an MHC class I-like heterodimer. Fc fragment of IgG, receptor, transporter, alpha (FCGRT) binds to the Fc region of monomeric immunoglobulins gamma and mediates the uptake of IgG from milk. FCGRT possible role in transfer of immunoglobulin G from mother to fetus. Beta-2-microglobulin (B2M) is a component of the class I major histocompatibility complex (MHC) and involved in the presentation of peptide antigens to the immune system.

Source:
MABSol® Biotinylated Cynomolgus / Rhesus macaque FcRn Heterodimer Protein (FCM-C82W5) is expressed from human HEK293 cells. It contains AA Ala 24 - Ser 297 (FCGRT) & Ile 21 - Met 119 (B2M) (Accession # Q8SPV9 (FCGRT) & Q8SPW0 (B2M)). In the region Ala 24 - Ser 297 (FCGRT) & Ile 21 - Met 119 (B2M), the AA sequence of Cynomolgus and Rhesus macaque FcRn (FCGRT & B2M) are homologus.
Predicted N-terminus: Ala 24 (FCGRT) & Ile 21 (B2M)

Molecular Characterization
The subunit FCGRT carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag. The subunit Beta-2 microglobulin (B2M) carries a Strep II tag at the C-terminus. The protein has a calculated MW of 34.1 kDa (FCGRT), 13.0 kDa (B2M) . The protein migrates as 40 kDa (FCGRT), 14 kDa (B2M) respectively on a SDS-PAGE gel under reducing (R) condition due to glycosylation. Cynomolgus and Rhesus macaque FcRn / FCGRT & B2M sequences are identical.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22µm filtered solution in PBS (pH 7.4) with Trehalose as protectant.
Contact us for customized product form or formulation.

Reconstitution
Please see Certificate of Analysis for specific instructions.For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. No activity loss is observed after storage at: 4-8°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution.

Biotin:Protein Ratio
The biotin to protein ratio is 0.5-1 as determined by the HABA assay.

Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrosbiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.

References

(1) Goebl NA., et al., 2008, Mol. Biol. Cell 19 (12): 5490–505.
(2) Lee TY., et al., 2008, Clin. Cancer Res. 14 (5): 1487–93.
(3) Güssow D., et al., 1987, J. Immunol. 139 (9): 3132–8.
(4) Gorevic P.D., et al., 1986, Proc. Natl. Acad. Sci. U.S.A. 83:7908-7912.

The following products could also be interesting for you: